Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.

Allen TD, Zhu CQ, Jones KD, Yanagawa N, Tsao MS, Bishop JM.

Cancer Res. 2011 Mar 15;71(6):2212-21. doi: 10.1158/0008-5472.CAN-10-3590.

2.

Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.

Allen TD, Rodriguez EM, Jones KD, Bishop JM.

Cancer Res. 2011 Sep 15;71(18):6010-8. doi: 10.1158/0008-5472.CAN-11-0595. Epub 2011 Jul 29.

3.

WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.

Wu C, Wang S, Xu C, Tyler A, Li X, Andersson C, Oji Y, Sugiyama H, Chen Y, Li A.

Cell Physiol Biochem. 2015;35(2):647-62. doi: 10.1159/000369726. Epub 2015 Jan 28.

4.

Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients.

Nakashima T, Liu D, Nakano J, Ishikawa S, Yokomise H, Ueno M, Kadota K, Huang CL.

Oncol Rep. 2008 Jan;19(1):203-9.

PMID:
18097596
5.

EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD, Wu CW.

Cancer Res. 2010 Nov 1;70(21):8822-31. doi: 10.1158/0008-5472.CAN-10-0638. Epub 2010 Oct 26.

6.

Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.

Li Z, Qu L, Zhong H, Xu K, Qiu X, Wang E.

Oncol Rep. 2014 Apr;31(4):1707-14. doi: 10.3892/or.2014.3050. Epub 2014 Feb 24.

PMID:
24573418
7.

Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.

Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II.

Clin Cancer Res. 2011 Apr 15;17(8):2434-43. doi: 10.1158/1078-0432.CCR-10-1412. Epub 2011 Jan 21.

8.

Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.

Meyer SE, Hasenstein JR, Baktula A, Velu CS, Xu Y, Wan H, Whitsett JA, Gilks CB, Grimes HL.

Am J Pathol. 2010 Sep;177(3):1503-13. doi: 10.2353/ajpath.2010.090651. Epub 2010 Jul 16.

9.

Human RNA polymerase II associated factor 1 complex promotes tumorigenesis by activating c-MYC transcription in non-small cell lung cancer.

Zhi X, Giroux-Leprieur E, Wislez M, Hu M, Zhang Y, Shi H, Du K, Wang L.

Biochem Biophys Res Commun. 2015 Oct 2;465(4):685-90. doi: 10.1016/j.bbrc.2015.08.017. Epub 2015 Aug 15. Erratum in: Biochem Biophys Res Commun. 2015 Dec 25;468(4):934.

PMID:
26282204
10.

Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax.

Sirzén F, Zhivotovsky B, Nilsson A, Bergh J, Lewensohn R.

Lung Cancer. 1998 Oct;22(1):1-13.

PMID:
9869102
11.

Candidate tumour suppressor CCDC19 regulates miR-184 direct targeting of C-Myc thereby suppressing cell growth in non-small cell lung cancers.

Liu Z, Mai C, Yang H, Zhen Y, Yu X, Hua S, Wu Q, Jiang Q, Zhang Y, Song X, Fang W.

J Cell Mol Med. 2014 Aug;18(8):1667-79. doi: 10.1111/jcmm.12317. Epub 2014 Jun 26.

12.

Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer.

Suzuki C, Takahashi K, Hayama S, Ishikawa N, Kato T, Ito T, Tsuchiya E, Nakamura Y, Daigo Y.

Mol Cancer Ther. 2007 Feb;6(2):542-51.

13.

MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.

Labisso WL, Wirth M, Stojanovic N, Stauber RH, Schnieke A, Schmid RM, Krämer OH, Saur D, Schneider G.

Cell Cycle. 2012 Apr 15;11(8):1593-602. doi: 10.4161/cc.20008. Epub 2012 Apr 15.

PMID:
22456335
14.

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.

Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao Y, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE, Wong KK.

Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.

15.

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.

Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, Hong SI, Lee KH, Choe TB, Park IC.

J Thorac Oncol. 2011 Aug;6(8):1313-9. doi: 10.1097/JTO.0b013e318220caff.

16.

Wnt3 gene expression promotes tumor progression in non-small cell lung cancer.

Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H.

Lung Cancer. 2012 May;76(2):228-34. doi: 10.1016/j.lungcan.2011.10.007. Epub 2011 Nov 8.

PMID:
22070884
17.

Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer.

Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoenissen NH, Huge A, Voss R, Marra A, Faldum A, Müller-Tidow C, Berdel WE, Wiewrodt R.

J Thorac Oncol. 2014 Sep;9(9):1294-304. doi: 10.1097/JTO.0000000000000243.

18.

[Relationships among expressions of hTERT, MDR1, MRP mRNA, and C-myc protein in non-small cell lung cancer].

Li L, Xiong YY, Liu L, Chen TX, Yao XF, Wang YW.

Ai Zheng. 2005 Jan;24(1):53-7. Chinese.

PMID:
15642200
19.

MYC is a metastasis gene for non-small-cell lung cancer.

Rapp UR, Korn C, Ceteci F, Karreman C, Luetkenhaus K, Serafin V, Zanucco E, Castro I, Potapenko T.

PLoS One. 2009 Jun 24;4(6):e6029. doi: 10.1371/journal.pone.0006029.

20.

[Expressions of APC and c-Myc and its implication on non-small cell lung cancer].

Wang SF, Liu Q, Zhang SF, Liao DY, Xu H, Zhang WY, Li WM, Liu LX.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Sep;41(5):822-6. Chinese.

PMID:
21302450

Supplemental Content

Support Center